Kiniksa Pharmaceuticals International Plc’s filing revealed that its CHIEF OPERATING OFFICER Tessari Eben unloaded Company’s shares for reported $0.47 million on Dec 16 ’24. In the deal valued at $20.44 per share,23,017 shares were sold. As a result of this transaction, Tessari Eben now holds 95,975 shares worth roughly $1.91 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Tessari Eben bought 23,017 shares, generating $470,373 in total proceeds.
Before that, Ragosa Mark sold 18,860 shares. Kiniksa Pharmaceuticals International Plc shares valued at $403,227 were divested by the CHIEF FINANCIAL OFFICER at a price of $21.38 per share. As a result of the transaction, Ragosa Mark now holds 22,958 shares, worth roughly $0.46 million.
Jefferies initiated its Kiniksa Pharmaceuticals International Plc [KNSA] rating to a Buy in a research note published on September 13, 2024; the price target was $40. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who began to cover the stock in early May with a ‘”an Overweight”‘ rating. BofA Securities also remained covering KNSA and reiterated its “Buy” recommendation on June 29, 2020. BofA/Merrill started covering the stock on April 01, 2020. It rated KNSA as “a Buy”.
Price Performance Review of KNSA
On Tuesday, Kiniksa Pharmaceuticals International Plc [NASDAQ:KNSA] saw its stock fall -1.53% to $19.94. Over the last five days, the stock has lost -2.68%. Kiniksa Pharmaceuticals International Plc shares have risen nearly 13.68% since the year began. Nevertheless, the stocks have risen 9.32% over the past one year. While a 52-week high of $28.15 was reached on 10/28/24, a 52-week low of $16.56 was recorded on 04/19/24. SMA at 50 days reached $22.61, while 200 days put it at $21.90.
Levels Of Support And Resistance For KNSA Stock
The 24-hour chart illustrates a support level at 19.73, which if violated will result in even more drops to 19.52. On the upside, there is a resistance level at 20.21. A further resistance level may holdings at 20.48. The Relative Strength Index (RSI) on the 14-day chart is 35.50, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.38, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 92.93%. Stochastics %K at 20.57% indicates the stock is a holding.
How much short interest is there in Kiniksa Pharmaceuticals International Plc?
A steep rise in short interest was recorded in Kiniksa Pharmaceuticals International Plc stocks on 2024-11-29, dropping by -0.2 million shares to a total of 4.02 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-31 was 4.21 million shares. There was a decline of -4.86%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on March 11, 2019 when Barclays began covering the stock and recommended ‘”an Overweight”‘ rating along with a $26 price target.
